Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: Comparative study with myocardial perfusion, left ventricular function, and histopathological findings

Annals of Nuclear Medicine

Volumn 17, Issue 6, 2003, Pages 481-488

  Saito, Kimimasa ^a   Takeda, Kan ^b   Imanaka Yoshida, Kyoko ^b   Imai, Hiroshi ^b   Sekine, Takao ^b   Kamikura, Yuko ^b  

^a ISE RED CROSS HOSPITAL   (Japan)

^b NONE

Author keywords

123I BMIPP; Cardiotoxicity; Docetaxel; Lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PACLITAXEL; RANITIDINE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; APPARATUS; ARTICLE; AUTOPSY; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DIAGNOSTIC IMAGING; DRUG INDUCED DISEASE; DRUG UPTAKE; EDEMA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SCINTIANGIOGRAPHY; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0141533074     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03006439     Document Type: Article

References (26)

1. Rowinsky EK, McGuire WP, Guamieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of Taxol. J Clin Oncol 1991; 9: 1704-1712.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
3. Saito K, Takeda K, Okamoto S, Okamoto R, Makino K, Tameda Y, et al. Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: Quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method. J Nucl Cardiol 2000; 7: 553-561.
4. Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT. J Nucl Med 1993; 34: 2216-2221.
5. Robert TD. Pharmacology of the taxanes. Pharmacology 1997; 5 (suppl): 96-104.
6. Sparano JA. Doxorubicin/taxane combinations: Cardiac toxicity and pharmacokinetics. Semin Oncol 1999; 26 (suppl): 14-19.
7. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-2699.
8. Dombernowsky P, Gehl J, Boesgaard M, Paaske T, Jensen BV. Doxorubicin and Paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 1996; 23 (suppl): 23-27.
9. Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, et al. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997; 15: 2510-2517.
10. Sparano JA. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations. Semin Oncol 1998; 25 (suppl): 66-71.
11. Nabholtz JM, Tonkin K, Smylie M, Mackey J, Janowska-Wieczorek A. Review of docetaxel and doxorubicin-based combinations in management of breast cancer: From metastatic to adjuvant setting. Semin Oncol 1999; 26 (suppl): 10-16.
12. Minotti G, Sponiero A, Licta S, Menna P, Calafiore AM, Teodori G, et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 2001; 7: 1511-1515.
13. Berg SL, Cowan KH, Balis FM, Fisherman JS, Denicoff AM, Hillig M, et al. Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994; 86: 143-145.
14. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 1993; 85: 388-394.
15. Chan S, Friedrichs K, Noel D, Pintér T, Belle SV, Vorobiof D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
16. Crown J. Phase III randomized trials of docetaxel in patients with metastatic breast cancer. Semin Oncol 1999; 26 (suppl): 33-38.
17. Kavanagh JJ, Kudelka AP, Leon CG, Tresukosol D, Hord M, Finnegan B, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clinical Cancer Research 1996; 2: 837-842.
18. Jekunen A, Heikkila P, Malche A, Pyrhönen S. Paclitaxel-induced myocardial damage detected by electron microscopy. Lancet 1994; 343 (letter): 727-728.
19. Sheck TW, Luk IS, Ma L, Cheung KL. Paclitaxel-induced cardiotoxity. An ultrastructual study. Arch Pathol Lab Med 1996; 120: 89-91.
20. Erland JFD, Poul KJ. Destruction of phospholipids and respiratory-chain activity in pig-heart submitochondrial particles induced by an adriamycin-iron complex. Eur J Biochem 1983; 132: 551-556.
21. Lampidis TJ, Kolonias D, Savaraj N, Rubin RW. Cardiostimulatory and antiarrhythmic activity of tubulin-binding agents. Proc Natl Acad Sci 1992; 89: 1256-1260.
22. Tsutsui H, Ishihara K, Cooper G. Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium. Science 1993; 260: 682-687.
23. Zile MR, Koide M, Sato H, Ishiguro Y, Conrad CH, Buckley JM, et al. Role of microtubules in the contractile dysfunction of hypertrophied myocardium. J Am Coll Cardiol 1999; 33: 250-260.
24. Danowski BA. Fibroblast contractility and actin organization are stimulated by microtubule inhibitors. J Cell Sci 1989; 93: 255-266.
25. Hirokawa H. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 1998; 279: 519-526.
26. Ioshii SO, Imanaka-Yoshida K, Yoshida T. Organization of calsequestrin-positive sarcoplasmic reticulum in rat cardiomyocytes in culture. J Cell Physiol 1994; 158: 87-96.